Nordic Nanovector to Present Pre-clinical Study of BetalutinŽ Effect on NHL Cells at European Hematology Association Meeting

Thursday, May 31, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

OSLO, Norway, May 31, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will present a poster describing

a preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin's lymphoma (NHL) cell lines to BetalutinŽ (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Stockholm,
Sweden
, 14-17 June). This preclinical study highlights the generally promising activity of BetalutinŽ against diffuse large B-cell lymphoma (DLBCL) cell lines.

The abstract is available online (click here) and the poster will be available on the company's website at: www.nordicnanovector.com following the presentation on 15 June.

Poster details Abstract  PF642 Abstract title:  Systems biology analysis of responsiveness of non-Hodgkin lymphoma B-cell lines to CD37 targeting radioimmunotherapy Authors: Melhus, KB et al. Date:   Friday 15 June Time:   17:30-19:00 (CEST)

For further information, please contact: Malene Brondberg, VPInvestor Relations and Corporate Communications Tel/Cell: + 44-7561-431-762 Email: ir@nordicnanovector.com

Media enquiries: Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: nordicnanovector@citigatedr.co.uk  

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is BetalutinŽ, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of BetalutinŽ in core markets. Further information about the Company can be found at www.nordicnanovector.com 

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector-to-present-preclinical-study-of-betalutin--effect-on-nhl-cells-at-european-hematol,c2536473

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-to-present-pre-clinical-study-of-betalutin-effect-on-nhl-cells-at-european-hematology-association-meeting-300657228.html

SOURCE Nordic Nanovector



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store